Dasatinib promotes lymphocyte egress from the spleen in a S1PR1-independent manner. (A) Experimental layout for egress assay. (B) Number of CFSE⁺ or endogenous B and T cells recovered from spleens of mice untreated or treated for 2 or 6 hours with DMSO or 50 mg/kg dasatinib. (C) Percentage of CFSE⁺ or endogenous cells recovered from spleens of dasatinib-treated mice normalized to DMSO-treated recipients (dotted line). n = 4 to 6 mice per group from 2 independent experiments; analyzed by 1-sample t test. (D) Experimental layout for egress assay in the presence of the S1PR1 agonist FTY720 (2 mg/kg). (E) Percentage of CFSE⁺ or endogenous cells normalized to DMSO-treated mice (dotted line). n = 6 mice per group from 3 independent experiments; analyzed by 1-sample t test. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001. Boxplots depict 25th and 75th percentiles and the median, and the whiskers show fifth and 95th percentiles. O/N, overnight.